Seelos Therapeutics Announces FDA Acceptance of Investigational
151
SEEL: Seelos Therapeutics, Inc. 2021-11-08 08:00:00 Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar Ataxia